To diagnose covid-19 effectively and cheaper, numerous Brazilian studies sought solutions to this challenge. Now, the National Health Surveillance Agency (Anvisa) has authorized the registration of a new serological test to identify antibodies to the SARS-CoV-2 coronavirus, developed by CT-Vaccinas. The group is formed by researchers from Fiocruz Minas — also known as the René Rachou Institute — and from the Federal University of Minas Gerais (UFMG).
- Pfizer elects a Brazilian city to evaluate the vaccine’s efficacy in the “real world”
- “SUS health posts will never be the same again”, says Luiza Trajano about vaccination
- MSD asks for authorization to use antiviral that reduces covid hospitalizations in 19%
The new covid test-19 was nicknamed Kit Elisa covid-10 IgG, because it is based on the Elisa immunoenzymatic method. In general, this method offers less risk for false negatives of covid-19, due to its high sensitivity . In other words, the strategies adopted by the Fiocruz test can detect low levels of antibodies and, therefore, it is considered more accurate.
In a previous interview with Agência Brasil, the researcher from CT- Vaccines, Flávio Fonseca, explained: “The test we developed detects the presence of antibodies against the virus. The serum is collected and the result analyzed in the laboratory, using an enzymatic reaction that is expressed in the reader”. At the time, the technology was still validated.
Want to catch up on the best tech news of the day? Go and subscribe to our new channel on youtube, Canaltech News. Every day a summary of the main news in the tech world for you!
Another differential is that the test can detect the main variants of the coronavirus. “The protein used in this test has a low mutation rate that is associated with the variants, which means that the test can identify the presence of the virus in any of these variants”, explains researcher Ricardo Gazzinelli, coordinator of the study.
Fiocruz’s covid test must be mass produced
The test was 97% developed in Brazil and, when mass produced, it should guarantee more autonomy for the country regarding the testing of covid-19. According to Gazzinelli, with the approval of Anvisa, the kit should already be distributed to the field laboratories.
According to a statement released by Fiocruz Minas, the scaling of processes and the entire production of the tests will be carried out by Instituto Bio-Manguinhos, another Fiocruz unit located in Rio de Janeiro.
To be developed, the project received support from RedeVírus, linked to the Ministry of Science, Technology and Information (MCTI) ), which earmarked about R$ 10 million. In addition, the Elisa Kit also received funding from the Research Support Foundation of Minas Gerais (Fapemig) and the National Institute of Vaccine Science and Technology (INCT-V).
Source: Fiocruz Minas and Agência Brasil
Did you like this article?
Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.